Why Is QuidelOrtho (QDEL) Stock Down -24.88% Today?
Key Takeaways
- QuidelOrtho shares plunged 24.88% during Friday's session, extending a sharp two-day selloff following the company's Q2 CY2026 earnings report.
- Primary catalyst: Despite beating Q2 revenue and EPS estimates, the company slashed its full-year FY2026 guidance — cutting revenue outlook by 6.1% and adjusted EPS guidance by 59.2% at the midpoint.
- Secondary drivers: Ongoing demand headwinds in China tied to proposed IVD pricing guidelines, a softer global respiratory environment, and downside in the Transfusion Medicine segment compounded investor concerns.
- Broader sector context: The healthcare diagnostics space faced broader risk-off sentiment during the session, adding pressure to an already reeling QDEL.
- What traders are watching: Potential asset sales — including the reported exploration of a $1.5 billion divestiture of its point-of-care testing business — and any stabilization in the China and respiratory testing markets.
Opening Summary
QuidelOrtho Corporation (QDEL), a major healthcare diagnostics company formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, saw its stock crater on Friday, tumbling 24.88% to approximately $12.26. The plunge follows Thursday's 6.7% decline, which brought shares to a close of $16.32. The selloff was triggered by the company's second-quarter fiscal 2026 earnings report, where a top- and bottom-line beat was entirely overshadowed by dramatically reduced full-year guidance, driven by deteriorating conditions in China and a weaker-than-expected global respiratory testing market.
Q2 Earnings Beat Overshadowed by Brutal Guidance Cut
QuidelOrtho reported Q2 CY2026 revenue of $630.9 million, up 2.8% year-over-year and ahead of the $618.1 million consensus estimate. Adjusted earnings per share came in at $0.13, handily beating analyst expectations of a $0.05 per-share loss. Adjusted EBITDA of $129.3 million also exceeded the Street's $109.3 million forecast, reflecting a 20.5% margin.
However, those headline beats were completely eclipsed by the company's forward-looking outlook. Management slashed its full-year FY2026 revenue guidance to $2.56 billion at the midpoint, down from $2.73 billion — a 6.1% reduction that landed approximately 5.4% below analyst estimates. Even more jarring was the cut to adjusted EPS guidance, which fell to $0.78 at the midpoint, a staggering 59.2% decline from prior expectations. Full-year EBITDA guidance of $550 million also came in well below the consensus estimate of roughly $615.8 million.
CEO Brian J. Blaser acknowledged the crosscurrents in his statement, saying, "Demand headwinds in China related to the proposed IVD pricing guidelines and a softer global respiratory environment are continuing to impact our business." The market's reaction reflected deep disappointment that operational challenges are worsening rather than stabilizing.
China Headwinds and Respiratory Weakness Deepen
A significant portion of QuidelOrtho's revenue pressure stems from China, where proposed In Vitro Diagnostics (IVD) pricing guidelines have disrupted demand across the company's product portfolio. While the company's Labs segment posted 4% revenue growth overall, performance outside of China was markedly stronger, with Labs revenue growing 9% when excluding the Chinese market. The Point of Care segment delivered a notable 16% revenue increase, but the Transfusion Medicine business saw a decline, further weighing on the overall picture.
The global respiratory testing market — which had been a massive growth driver during the COVID-19 pandemic era — has continued to soften, compounding the China-specific challenges. With respiratory pathogen demand tracking below historical norms, a key revenue pillar for QuidelOrtho remains under pressure, and the guidance cut signals that management does not anticipate a near-term recovery.
Market Context and Trading Activity
Trading volume in QDEL surged well above its daily average, reflecting intense institutional repositioning following the earnings and guidance shock. On Thursday alone, more than 2.7 million shares changed hands versus an average of approximately 1.76 million, and Friday's session continued to see elevated activity as the stock breached multiple technical support levels.
The broader healthcare diagnostics peer group traded mostly lower during the session, weighed down by geopolitical uncertainty and sector-wide risk-off sentiment. The move in QDEL significantly outpaced weakness in peers such as LNTH and XRAY, indicating that the selloff was predominantly company-specific rather than purely macro-driven. The stock sliced through its 50-day moving average and is now trading at levels not seen in months, with the 200-day moving average far above current prices.
What Comes Next for QDEL
The path forward for QDEL hinges on several factors. First, investors will closely monitor any developments regarding the potential sale of the company's point-of-care testing business, which reports have valued at approximately $1.5 billion. A successful divestiture could meaningfully reduce the company's $3.8 billion debt load, which has been a persistent overhang since the Ortho Clinical Diagnostics acquisition.
Second, stabilization in the Chinese IVD regulatory environment and any signs of a respiratory testing recovery would be critical catalysts for sentiment. Third, the company's ability to manage costs and protect margins against a weaker top-line backdrop will be scrutinized in the quarters ahead. With institutional ownership near 99%, further downward pressure could emerge if major holders decide to reduce exposure, though the stock's deeply discounted valuation relative to some intrinsic-value estimates may ultimately attract value-oriented buyers. Risks remain tilted to the downside until concrete evidence of operational stabilization emerges.
Trending AI Robots
In volatile market environments like the one currently impacting QDEL, traders often turn to AI-driven tools to help navigate sudden price swings. Tickeron's Trending AI Robots page features a curated selection of hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are showcased. These bots vary by strategy, timeframe, performance metrics, and traded symbols, offering diverse approaches for different market regimes. Explore the Trending AI Robots page to see which automated strategies are adapting best to today's market dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
QDEL's RSI Indicator ascending out of oversold territory
The RSI Oscillator for QDEL moved out of oversold territory on September 24, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 35 of the 43 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on QDEL as a result. In 56 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for QDEL just turned positive on September 28, 2026. Looking at past instances where QDEL's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
QDEL moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where QDEL advanced for three days, in 177 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QDEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
QDEL broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for QDEL entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.418) is normal, around the industry mean (10.853). P/E Ratio (9.756) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.274) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. QDEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QDEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of diagnostic healthcare solutions
Industry MedicalNursingServices
Advertisement